Temasek increased its holdings in INNOVENT BIO (01801) by 275,000 shares at a price of approximately HK$34.98 per share.
The latest information from the Hong Kong Stock Exchange shows that on January 7th, Temasek Holdings increased its holdings of Sino Biopharmaceutical (01801) by 275,000 shares, with a price of 34.9790 Hong Kong dollars per share, totaling approximately 9.6192 million Hong Kong dollars.
According to the latest data from the Hong Kong Stock Exchange, on January 7th, Temasek Holdings increased its holdings of INNOVENT BIO (01801) by 275,000 shares, with a price of 34.9790 Hong Kong dollars per share, totaling approximately 9.6192 million Hong Kong dollars. After the increase, the latest number of shares held is approximately 131 million shares, with the latest shareholding ratio of 8%.
Related Articles
New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?
Guosen: The final mindset of asset trend convergence.
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?
Guosen: The final mindset of asset trend convergence.
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
